Register Interest

AUM Biosciences

  • A disruptive biotechnology company developing first-in-class oncology small molecules, leveraging AI technologies and precision medicine to create a synergistic, sustainable, and scalable biopharma company. We have global rights in all indications of 2 novel oncology drugs in pipeline. AUM001 targets CML and CRC addressing a market size of $13B; AUM302 targets breasts cancer and neuroblastoma indications addressing a $18B market.